The life sciences industry faces an unprecedented number of challenges led by concerns about escalating healthcare costs. With a consolidating payer base increasingly driving healthcare decision-making, more evidence of both safety and effectiveness is required than randomized clinical trials (RCTs) — the familiar “gold standard” — can offer.

Against this background, real world evidence is an increasingly significant element of the clinical and health economic research agenda. It’s an important tool to understand performance throughout a product’s lifecycle, including adverse events. We spoke with members of the medical device and diagnostics industry, who shared how increasing demands for real world evidence are impacting their business.

Read More

Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.

Privacy is important. We do not share registrant information with anyone outside of Numerof & Associates. For details, please see our Privacy Policy. Subscribers to our mailings can unsubscribe instantly at any time.